for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Evolus Inc

EOLS.OQ

Latest Trade

18.72USD

Change

1.15(+6.55%)

Volume

560,542

Today's Range

17.68

 - 

19.00

52 Week Range

10.29

 - 

30.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
17.57
Open
17.71
Volume
560,542
3M AVG Volume
10.07
Today's High
19.00
Today's Low
17.68
52 Week High
30.25
52 Week Low
10.29
Shares Out (MIL)
27.42
Market Cap (MIL)
481.85
Forward P/E
-5.01
Dividend (Yield %)
--

Next Event

Evolus Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Evolus Expects 2019 Revenue To Be Back-loaded Towards Q4: Conf. Call

Evolus Says Gross Margins May Fluctuate In The Future Due To Various Marketing Programs

Evolus Posts Q2 Revenue Of $2.3 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Evolus Inc

Evolus, Inc. is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market. It offers physicians and patients a compelling value proposition with DWP-450. OnabotulinumtoxinA (BOTOX) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.

Industry

Biotechnology & Drugs

Contact Info

520 Newport Center Dr Ste 1200

+1.949.2844555

https://www.evolus.com

Executive Leadership

Vikram Malik

Chairman of the Board

David Moatazedi

President, Chief Executive Officer, Director

Lauren P. Silvernail

Chief Financial Officer, Executive Vice President - Corporate Development

Michael M Jafar

Chief Marketing Officer

Alejandro Sabad

Vice President - Operations

Key Stats

2.44 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-0.310

2018

-1.920

2019(E)

-3.508
Price To Earnings (TTM)
--
Price To Sales (TTM)
208.50
Price To Book (MRQ)
11.69
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
219.20
LT Debt To Equity (MRQ)
219.20
Return on Investment (TTM)
-48.88
Return on Equity (TTM)
-44.85

Latest News

Evolus reports sales of its Botox rival ahead of expectations

Medical aesthetics company Evolus Inc <EOLS.O> on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's <AGN.N> Botox, which has dominated the medical aesthetics market for more than a decade.

Evolus says launch of its Botox rival ahead of its expectations

Evolus Inc on Monday reported revenue of $2.3 million from early sales of its newly launched rival to Allergan Plc's Botox, ahead of its own expectations.

FDA approves cheaper Botox rival to treat frown lines

(This Feb. 1 story has been corrected to remove reference to dosage in paragraph 7)

BRIEF-Evolus Announces Pricing Of Initial Public Offering Of Common Stock

* EVOLUS, INC. ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF COMMON STOCK

BRIEF-Evolus Inc Sees IPO Priced To Be Between $12 And $14 Per Share

* EVOLUS INC SEES IPO OF 5 MILLION SHARES PRICED TO BE BETWEEN $12 AND $14 PER SHARE – SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up